<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001431</url>
  </required_header>
  <id_info>
    <org_study_id>950075</org_study_id>
    <secondary_id>95-C-0075</secondary_id>
    <nct_id>NCT00001431</nct_id>
  </id_info>
  <brief_title>A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas</brief_title>
  <official_title>A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Radiotherapy plus Single-Agent Chemotherapy/Radiosensitization. Involved-field irradiation&#xD;
      using 4-15 MV photons; plus Gemcitabine, NSC-613327.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I trial of gemcitabine given weekly as a 30 minute infusion administered&#xD;
      concurrently with radiation in patients with locally advanced or locally recurrent pancreatic&#xD;
      carcinoma. Patients will be treated with external beam radiation therapy in a standard&#xD;
      manner. Gemcitabine will be administered as a 30 minute infusion beginning on the first day&#xD;
      of irradiation and weekly afterwards for a total of 5 doses. Patients will be assessed&#xD;
      clinically for acute toxicity which will be graded per RTOG and DCT toxicity grading system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1995</start_date>
  <completion_date>November 2000</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>20</enrollment>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Pancreatic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Histologically or cytologically proven unresectable adenocarcinoma of the pancreas or&#xD;
        ampulla of Vater. Surgical consult at NCI confirming unresectability fulfills requirement.&#xD;
&#xD;
        Unresectable disease defined as tumor with: Gross involvement of regional nodes or direct&#xD;
        extension to any of the following sites: Duodenum, Spleen, Bile duct , Colon,&#xD;
        Peripancreatic tissue, Adjacent large vessels, Stomach.&#xD;
&#xD;
        Metastatic disease requiring local radiotherapy allowed. No CNS metastasis.&#xD;
&#xD;
        No lymphomas or neuroendocrine tumors.&#xD;
&#xD;
        No peritoneal carcinomatosis.&#xD;
&#xD;
        PRIOR/CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic Therapy: More than 4 weeks since immunotherapy.&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
        No prior chemotherapy for newly diagnosed disease.&#xD;
&#xD;
        More than 4 weeks since chemotherapy for recurrent disease (6 weeks since nitrosoureas,&#xD;
        mitomycin, or suramin).&#xD;
&#xD;
        Endocrine Therapy: More than 4 weeks since hormonal therapy.&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
        No prior radiotherapy for newly diagnosed disease.&#xD;
&#xD;
        No prior abdominal or pelvic radiotherapy.&#xD;
&#xD;
        More than 4 weeks since radiotherapy for recurrent disease. No prior radiotherapy for&#xD;
        locally advanced disease after resection allowed.&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
        Prior resection allowed.&#xD;
&#xD;
        Biliary decompression or gastric bypass allowed.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age: 18 and over.&#xD;
&#xD;
        Performance status: ECOG 0-2.&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
        ANC greater than 2,000/mm(3).&#xD;
&#xD;
        Platelets greater than 100,000/mm(3).&#xD;
&#xD;
        Hepatic: AST/ALT no greater than 2.5 times normal.&#xD;
&#xD;
        Renal:&#xD;
&#xD;
        Creatinine less than 1.5 mg/dL.&#xD;
&#xD;
        Creatinine clearance at least 60 mL/min,&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
        No myocardial infarction within 6 months.&#xD;
&#xD;
        No unstable angina.&#xD;
&#xD;
        No congestive heart failure (NYHA class III/IV).&#xD;
&#xD;
        OTHER:&#xD;
&#xD;
        HIV seronegative.&#xD;
&#xD;
        No medical or psychiatric contraindication to protocol therapy.&#xD;
&#xD;
        No concurrent malignancy other than: Skin cancer, Cervical carcinoma in situ.&#xD;
&#xD;
        No pregnant or nursing women.&#xD;
&#xD;
        Adequate contraception required of fertile patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Morohoshi T, Held G, Kloppel G. Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases. Histopathology. 1983 Sep;7(5):645-61. doi: 10.1111/j.1365-2559.1983.tb02277.x.</citation>
    <PMID>6313514</PMID>
  </reference>
  <reference>
    <citation>Rosenberg JM, Welch JP, Macaulay WP. Cancer of the head of the pancreas: an institutional review with emphasis on surgical therapy. J Surg Oncol. 1985 Mar;28(3):217-21. doi: 10.1002/jso.2930280315.</citation>
    <PMID>2579295</PMID>
  </reference>
  <verification_date>November 2000</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Combined Modality</keyword>
  <keyword>GI Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

